drugset / Trial / NCT00392717

Regulation of Lipoprotein Metabolism in Obese Men

NCT00392717

Phase 3 Completed 48 enrolled The University of Western Australia
RandomizedFactorialDouble-blindTreatment

Summary

Visceral obesity is strongly associated with dyslipidaemia (hypertriglyceridaemia, low HDL-cholesterol and mildly elevated LDL-cholesterol) and insulin resistance, key characteristics of metabolic syndrome (MetS). Recent evidence has clearly established that the risk of CVD is increased in subjects with the MetS. The precise reason for this remains unclear, but appears to be closely related with dyslipidaemia. Effective management of dyslipidaemia is important to reduce the risk of CVD in these subjects. Hypothesis: Inhibition of hepatic cholesterol synthesis by statins and triglyceride synthesis by fish oils improve lipoprotein metabolism in visceral obese men.

Timeline

Start
1998-02
Primary completion
Completion
2002-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule
Subject Omega-3 fatty acids Unknown